Dehydrated Human Amnion/Chorion Membrane (dHACM) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face
A Single Center, Double Blinded, Placebo Controlled, Randomized, Split Face Study to Evaluate the Efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The purpose of this study is to evaluate the efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for reducing time to healing when used in post-laser recovery following ActiveFX™ and DeepFx™ fractionated ablative CO2 laser resurfacing of the face.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Sep 2013
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2013
CompletedFirst Submitted
Initial submission to the registry
November 21, 2013
CompletedFirst Posted
Study publicly available on registry
November 26, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2013
CompletedJune 13, 2014
June 1, 2014
2 months
November 21, 2013
June 12, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
The time to healing for both groups will be assessed as defined by appearance and 100% epithelialization.
Day 30
Secondary Outcomes (1)
Erythema, edema, crusting, and exudate will be compared between both groups.
30 Days
Other Outcomes (1)
Pain Reduction
30 Days
Study Arms (2)
dHACM
EXPERIMENTALUltraPulse laser therapy with application of dHACM
Sterile 0.9% Saline Solution
PLACEBO COMPARATORUltraPulse laser therapy with application of Sterile 0.9% Saline Solution
Interventions
Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
Eligibility Criteria
You may qualify if:
- Male or female subjects in good general health greater than 18 years of age
- Must be willing to agree to all terms of the protocol and provide a completed and signed informed consent, HIPAA and photography release forms
- Subjects planning to undergo fractionated ablative CO2 laser resurfacing to the full face
- Subject of either Fitzpatrick Skin Types I, II or III
- For female subjects of childbearing potential, they must have had a regular menstrual cycle prior to study entry and is willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use at least 30 days prior to entry into the study. A female is considered NOT to be of childbearing potential if she is postmenopausal for at least one (1) year, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants Norplant, Depo-Provera, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of the partner.
- Negative urine pregnancy test results at the time of study entry for females of childbearing potential, if applicable
- Must be willing to comply with study instructions and complete the entire course of the study
You may not qualify if:
- Any uncontrolled systemic disease that is not yet stabilized for at least one (1) year
- A significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would interfere with the objectives of the study
- Recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days of study entry
- History of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis)
- Active bacterial, fungal, or viral infection
- History of Herpes Simplex Virus to the facial and/or perioral areas
- Known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-aminobenzoic acid), or other local anesthetics of the amide or ester family
- Known allergies to gentamicin and/or streptomycin
- Receiving any topical products containing alpha-hydroxy acids, salicylic acid, and Vitamins C or E (including derivatives of Vitamins C or E) on the face within 14 days prior to or during the study period, other than the ingredients of the study products
- Receiving and/or has had a microdermabrasion (light or medium skin peel) treatment on their face within 30 days prior to or during the study period
- Using any topical tretinoin product or derivative on their face within 12 weeks prior to or during the study period
- Receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio frequency treatment and/or has had a Dermabrasion (deep skin peel) or ablative laser treatments on their face must have discontinued the drug/treatment and/or had the procedure at least 3 months prior to entering the study
- History of keloids or hypertrophic scars
- Use of systemic retinoids, prescription or over-the-counter grade within the past year
- A female subject who is pregnant, nursing an infant or planning a pregnancy during the study
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dermatology Cosmetic Laser Medical Associates of LaJolla, Inc.
San Diego, California, 92121, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mitchel P Goldman, MD
Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 21, 2013
First Posted
November 26, 2013
Study Start
September 1, 2013
Primary Completion
November 1, 2013
Study Completion
December 1, 2013
Last Updated
June 13, 2014
Record last verified: 2014-06